Determination of Antimicrobial Resistance Pattern and Production of Extended-Spectrum Β-Lactamases amongst Escherichia coli and Klebsiella pneumoniae from Clinical Isolates
,
Abstract
Background: The prevalence of antibiotic resistance among extended spectrum β-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae has been increased markedly in recent years. The present study was done to know the prevalence of ESBL production among isolates of E. coli and K. pneumoniae and to study the susceptibility pattern of isolates against different antibiotics.
Methods: Extended spectrum β-lactamase producing E. coli and K.pneumoniae were isolated from various samples obtained from outdoor and indoor patients of the Prathima Institute of medical sciencesdisc synergy test and resistance to various antibiotics like fluoroquinolones, cephalosporins, aminoglycosides and ß-lactamase inhi- bitor combinations and susceptibility to carbapenems were determined by Kirby-Bauer disc diffusion method.
Results: A total of 94 ESBL producing isolates were obtained. Of them 60 were E. coli and 34 K. pneumoniae. They were obtained from urine, sputum, pus, wound swabs blood & tracheal aspirates. Urine (38.29%) was the main source of ESBL-producing isolates from all patients, fol lowed by sputum (34.04%). About 37.23% of these isolates were collected from medical wards and 27.65% were collected from outdoor. All isolates were susceptible to imipenem. The resistance to cephalos porins (1-4 generations) was almost 100%. Resistance to Aztreonam, Ampicillin and Coamoxyclav was also 100%. A high degree of resis tance was observed to other antibiotics.
Conclusion: The highest prevalence of resistance to ESBL in E. coli and K. pneumonia is associated with a multitude of infections in hospi talized patients with a significant longer duration of hospital stay, increased morbidity and greater hospital charges. Advanced drug resistance surveillance and molecular characteristics of ESBL isolates is ne- cessary to guide the proper and judicious antibiotic use.
Mehrgan H, Rahbar M. Prevalence of extended-spectrum beta-lactamase pr oducing Escherichia coli in a tertiary care hospital in Tehran, Iran. Int J Antimicrob Agents 2008; 31 (2): 147-51.
Turner PJ. Extended spectrum β-Lac tamases. Clin Infect Dis 2005; 41 (su ppl 4): S273-75.
Paterson DL, Bonomo RA. Extended- Spectrum β-Lactamases: a Cli nical Update. Clin Microbiol Rev 2005; 18 (4): 657-86.
Knothe A, Shah P, Kremery V, et al.Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime and in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11 (6): 315-7.
Jacoby GA, Medeiros AA, O’Brien TF, et al. Broad-spectrum transmissible be- ta-lactamases. N Engl J Med 1989; 319 (11): 723-4.
Quinn JP, Miyashiro D, Sahm D, et al.Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1989; 33 (9): 1451-6.
Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by Extended-spectrum β-lactamase pro ducing Klebsiella pneumoniae: Risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50 (2): 498-504.
Lautenbach E, Patel JB, Bilker WB, et al. Extended-Spectrum β-Lactama se producing Escherichia coli and Klebsiella pneumoniae: Risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32 (8): 1162-71.
Lee SY, Kotapati S, Kuti JL, et al.Impact of Extended-Spectrum β-Lac tamase-producing Escherichia coli and Klebsiella Species on clinical out- comes and hospital costs: A matched cohort study. Infect Control Hosp Epidemiol 2006; 27 (11): 1226.
Schwaber MJ, Navon-Venezia S, Ka ye KS, et al. Clinical and economic Impact of bacteremia with extended spectrum-β-Lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50 (4):1257-1262.
Winn WC, Allen S, Janda WM, Kone- man EW, Schreckenberger PC, Procop G, Baker Woods G., 2006. Koneman's Color Atlas and Textbook of Diagnos-tic Micryobiology, 6th ed. Williams and Wilkins, Lippincott.
Performance Standards for Antimi- crobial Susceptibility Testing; Twenty First Informational Supplement. CLSI document M100-S21 (ISBN 1-56238-
-1). Clinical and Laboratory Stand- ards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087 USA, 2011.
Alipourfard I, Yeasmin Nili N. Anti- biogram of Extended Spectrum Beta- lactamase (ESBL) producing Esche- richia coli and Klebsiella pneumoniae isolated from Hospital Samples Bang- ladesh. J Med Microbiol 2010; 4 (1):32-36
Khanfar HS, Bindayna KM, Senok AC, et al. Extended spectrum beta- lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings. J Infect Dev Ctries 2009; 3 (4): 295-9.
Meyer KS, Urban C, Eagen JA, et al.Nosocomial outbreak of Klebsiella in- fection resistant to late-generation cephalosporins. Ann Intern Med 1993;119 (5): 353-8.
Shanthi M , Sekar U. Extended spec- trum beta lactamase producing Esche- richia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. J Assoc Physicians India 2010; 58:41-44.
Babypadmini S, Appalaraju B. Ex- tended spectrum lactamase in urinary isolates of Escherichia coli and Klebsiella pneumoniae – prevalence and susceptibility pattern in a Tertiary care hospital. Indian J Med Microbiol 2004; 22 (3): 172-4.
Lucet JC, Chevret S, Decré D, et al.Outbreak of multiply resistant Ente- robacteriaceae in an intensive care unit: epidemiology and risk factors for ac- quisition. Clin Infect Dis 1996; 22 (3):430-6.
Paterson DL, Ko WC, Mohapatra S, et al. Program and abstracts of the 37th Interscience Conference on Antimi- crobial Agents and Chemotherapy (To- ronto). Washington, DC: American Society for Microbiology; 1997. Klebsiella pneumoniae bacteremia: impact of extended-spectrum β- lactamase (ESBL) production in a global study of 216 patients .
| Files | ||
| Issue | Vol 1 No 3-4 (2012) | |
| Section | Original Articles | |
| Keywords | ||
| beta-Lactamases Escherichia coli Klebsiella pneumoniae | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
